Zobrazeno 1 - 10 of 41 pro vyhledávání: '"Stuart, Friedrich"'
3
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
Autor: Michael Durante, Jochen Schmitz, Stuart Friedrich, Elina Berliba, Jay Tuttle, Toshifumi Hibi, Bal R. Bhandari, Janelle Laskowski, Marc Ferrante, William J. Sandborn, MaryAnn Morgan-Cox, Geert R. D'Haens, Brian G. Feagan, Paul Klekotka
Publikováno v: Gastroenterology, 158(3), 537-549.e10. W.B. Saunders Ltd
BACKGROUND & AIMS: Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of interleukin 23, in a phase 2 study of patients with UC. METHODS
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45a62eed3231d132fa474bb9f7b87db6
https://lirias.kuleuven.be/handle/123456789/641700
Zobrazit plný text záznamu
4
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study
Autor: Alan Menter, Kim Papp, C. Leonardi, Dipak R. Patel, Robert Bissonnette, MaryAnn Morgan-Cox, Catherine Maari, Jay Tuttle, Amaf investigators, Kristian Reich, Atsuyuki Igarashi, J Li, Paul Klekotka, Emily Edson-Heredia, Phoebe Rich, Stuart Friedrich
Publikováno v: The British journal of dermatology. 181(1)
BACKGROUND Inhibiting interleukin (IL)-23 in patients with psoriasis has demonstrated high levels of skin clearance. OBJECTIVES To investigate, in a phase II (AMAF; NCT02899988), multicentre, double-blind trial, the efficacy and safety of three doses
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc8693a4d3e0faed648b9a48d542a22f
https://pubmed.ncbi.nlm.nih.gov/30734266
Zobrazit plný text záznamu
5
Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis
Autor: Stuart Friedrich, Emmanuel Chigutsa, Kimberley Jackson, Nieves Velez de Mendizabal, Kristian Reich, Michael Heathman, Laiyi Chua
Publikováno v: Journal of clinical pharmacology. 58(11)
Ixekizumab, a high-affinity monoclonal antibody, selectively targets interleukin-17A and has been shown to be efficacious in the treatment of moderate to severe psoriasis. The objective was to describe the relationship between ixekizumab concentratio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a3b3a31b516c99dff66c194c396fc1
https://pubmed.ncbi.nlm.nih.gov/29878382
Zobrazit plný text záznamu
7
CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
Autor: Ming Dauh Wang, Stephen J. Nicholls, Ellen A. Cannady, Stuart Friedrich, Jessica Rehmel, Jeffrey G. Suico, Kathryn A. Krueger
Publikováno v: British Journal of Clinical Pharmacology
Aims Evacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor under development for reducing cardiovascular events in patients with high risk vascular disease. CETP inhibitors are likely to be utilized as ‘add-on’ therapy to statins i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5dda0ae8262820a61d7f382c8550169
http://europepmc.org/articles/PMC4693478
Zobrazit plný text záznamu
8
A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State
Autor: Delyn Downs, Jane Royalty, David S. Small, Ellen A. Cannady, Jeffrey G. Suico, Wei Zhang, Stuart Friedrich
Publikováno v: Journal of Cardiovascular Pharmacology and Therapeutics
Purpose: To determine the effect of a high-fat meal on evacetrapib exposure at steady state in healthy participants. Methods: This was a randomized, 2-period, 2-sequence, open-label, crossover study. Patients were randomly assigned to 1 of the 2 trea
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d327f9e7ce86be6c7afeebe081c2ec12
https://doi.org/10.1177/1074248415575153
Zobrazit plný text záznamu
9
Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches
Autor: Nathan Bryan Mantlo, Stephen D. Hall, Stuart Friedrich, Matthew Rotelli, Alice Ban Ke, David S. Small
Publikováno v: The Journal of Clinical Pharmacology. 55:757-767
Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor, has been reported to have longer elimination half-life after longer treatment. Two pharmacokinetic model-based approaches were used to assess whether evacetrapib, another CETP inhibi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de10d9a7ddf9d57b1ec1982284c5681f
https://doi.org/10.1002/jcph.472
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje